View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
August 9, 2019

Dynacure secures orphan drug designation from FDA for DYN101

Dynacure has secured orphan drug designation from the US Food and Drug Administration (FDA) for investigational antisense medicine DYN101, which has been designed to modulate the expression of dynamin 2 (DNM2) to treat Centronuclear Myopathies (CNM).

Dynacure has secured orphan drug designation from the US Food and Drug Administration (FDA) for investigational antisense medicine DYN101, which has been designed to modulate the expression of dynamin 2 (DNM2) to treat Centronuclear Myopathies (CNM).

During the second half of this year, the company expects to initiate a Phase I / II in human study ‘Unite-CNM’ of DYN101, which is being developed in collaboration with Ionis Pharmaceuticals.

CNM are serious, rare, life-threatening disorders that affect skeletal muscles from birth and are driven by mutations in multiple genes including MTM1, DNM2 and BIN1.

Dynacure CEO Stephane van Rooijen said: “Orphan drug designation in the US is a critically important regulatory milestone in our global development plan for DYN101 to treat several forms of centronuclear and myotubular myopathies.

“The US designation complements our orphan drug designation in the EU and we look forward to enrolling in our first-in-human clinical study with DYN101 later this year to treat this devastating, rare disease.”

Drugs that seek to treat a rare disease or condition tend to always secure orphan drug designation from the FDA.

Furthermore, the designation provides seven years of market exclusivity if approved, in addition to significant development incentives, including tax credits related to clinical trial expenses.

Based on preclinical studies, DYN101 has the potential to be disease-modifying in CNM, with compelling preclinical efficacy in treating animal models of XLCNM and ADCNM2.

In January, the company secured orphan drug designation from the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) for DYN101 to treat CNM.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU